Tirzepatide Treatment and Associated Changes in β-Cell Function and Insulin Sensitivity in People With Obesity or Overweight With Prediabetes or Normoglycemia: A Post Hoc Analysis From the SURMOUNT-1 Trial
Authors' conclusion
In adults with obesity/overweight without type 2 diabetes, tirzepatide treatment was associated with improved β-cell function and insulin sensitivity, partly independent of weight reduction.
Study context
- Population
- Adults with BMI ≥27 kg/m² without diabetes, with prediabetes or normoglycemia at baseline
- Participants
- 2,539 adults
- Comparison
- Tirzepatide vs placebo
- Primary endpoint
- Model-derived parameters of β-cell function and insulin sensitivity from OGTTs
- Follow-up
- Week 72
Methodological detailspost hoc analysis
- Post hoc analysis
Primary result
As reported in the abstract
Insulin sensitivity and β-cell function
- Tirzepatide associated with body weight reduction and improvements in insulin sensitivity and β-cell function measures, overall and in prediabetes or normoglycemia
- In multivariate regression, insulin sensitivity improvements associated mostly with weight reduction and partly with tirzepatide; β-cell function enhancement mostly associated with tirzepatide
Original publication
Tirzepatide Treatment and Associated Changes in β-Cell Function and Insulin Sensitivity in People With Obesity or Overweight With Prediabetes or Normoglycemia: A Post Hoc Analysis From the SURMOUNT-1 Trial. Diabetes Care. Published 22 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →